Ukususela ekufikeni kweemveliso ze-NMN, ziye zaziwa ngegama elithi "elixir lokungafi" kunye "neyeza lokuphila ixesha elide", kunye ne-NMN concept stocks ezinxulumene nazo ziye zafunwa yimarike. U-Li Ka-shing uthathe i-NMN ixesha elithile, kwaye emva koko wachitha i-200 yezigidi zeedola zaseHong Kong kuphuhliso lwe-NMN, kwaye inkampani kaWarren Buffett nayo yafikelela kwintsebenziswano yeqhinga kunye nabavelisi be-NMN. Ngaba i-NMN, ethandwa zizityebi eziphezulu, ingaba nefuthe lokuphila ixesha elide?
I-NMN yi-nicotinamide mononucleotide (i-Nicotinamide mononucleotide), igama elipheleleyo yi-"β-nicotinamide mononucleotide", ephuma kudidi lwe-vitamin B kunye ne-precursor ye-NAD+, enokuguqulwa ibe yi-NAD+ ngesenzo soluhlu lwee-enzymes. emzimbeni, ngoko ke ukuxhaswa kwe-NMN kuthathwa njengendlela esebenzayo yokuphucula amanqanaba e-NAD+. I-NAD + yeyona nto iphambili kwi-intracellular coenzyme ebandakanyeka ngokuthe ngqo kumakhulu eempendulo ze-metabolic, ngakumbi ezo zinxulumene nokuveliswa kwamandla. Njengoko sikhula, amanqanaba e-NAD + emzimbeni ehla ngokuthe ngcembe. Ukuncipha kwe-NAD+ kuya kuphazamisa amandla eeseli ukuvelisa amandla, kwaye umzimba uya kuba neempawu eziwohlokayo ezinjengokuncipha kwezihlunu, ukulahleka kwengqondo, umbala webala, ukulahleka kweenwele, njl.
Emva kweminyaka ephakathi, inqanaba le-NAD + emzimbeni wethu lehla ngaphantsi kwe-50% yenqanaba elincinci, yiyo loo nto emva kweminyaka ethile, kunzima ukubuyela kwimeko yobutsha nokuba uphumle kangakanani. Amanqanaba asezantsi e-NAD + anokukhokelela kwizifo ezininzi ezinxulumene nokwaluphala, kubandakanya i-atherosclerosis, isifo samathambo, uxinzelelo lwegazi oluphezulu, isifo sentliziyo, ukwehla kwengqondo, izifo ze-neurodeergenerative, isifo seswekile, kunye nomhlaza, phakathi kwabanye.
Ngo-2020, uphando loluntu lwenzululwazi kwi-NMN lwalusebuntwaneni, kwaye phantse zonke iimvavanyo zazisekwe kuvavanyo lwezilwanyana kunye nempuku, kwaye uvavanyo lwezonyango lomntu kuphela ngo-2020 ngelo xesha lwaqinisekisa kuphela "ukhuseleko" lwezongezo zomlomo ze-NMN, kwaye akazange aqinisekise ukuba inqanaba le-NAD + emzimbeni womntu liye landa emva kokuthatha i-NMN, ingasathethi ke ukuba inokulibazisa ukuguga.
Ngoku, kwiminyaka emine emva koko, kukho ukuqhubela phambili kophando olutsha kwi-NMN.
Kuvavanyo lwezonyango lweentsuku ezingama-60 olwapapashwa ngo-2022 kumadoda angama-80 akubudala obuphakathi, izifundo ezithatha i-600-900mg ye-NMN ngosuku zaqinisekiswa ukuba ziyasebenza ekwandiseni amanqanaba e-NAD+ egazini, kwaye xa kuthelekiswa neqela le-placebo, izifundo bathatha i-NMN ngomlomo yokwandisa umgama wabo wokuhamba ngomzuzu we-6, kwaye ukuthatha i-NMN kwiiveki ze-12 ezilandelelanayo kunokuphucula umgangatho wokulala, ukuphucula umsebenzi womzimba, kunye nokuphucula amandla omzimba, njengaye. ukuqinisa amandla okubamba, ukuphucula isantya sokuhamba, njl. Ukunciphisa ukukhathala nokulala, ukwandisa amandla, njl.
I-Japan yayililizwe lokuqala ukuqhuba iimvavanyo zeklinikhi ze-NMN, kwaye i-Keio University School of Medicine yaqala isigaba se-II solingo lweklinikhi kwi-2017 emva kokugqiba isigaba soku-I solingo lonyango ukuqinisekisa ukhuseleko. Uphando lovavanyo lweklinikhi lwenziwa yiShinsei Pharmaceutical, eJapan kunye neSikolo seSidanga seSayensi yeBiomedical kunye neMpilo, iYunivesithi yaseHiroshima. Uphononongo, olwaqala ngo-2017 unyaka kunye nesiqingatha, lujolise ekufundeni imiphumo yezempilo yokusetyenziswa kwexesha elide le-NMN.
Ngethuba lokuqala kwihlabathi, kuye kwaqinisekiswa ngokweklinikhi ukuba ukubonakaliswa kweprotheni yokuphila ixesha elide kwanda emva kokulawulwa komlomo we-NMN kubantu, kwaye ukubonakaliswa kweentlobo ezahlukeneyo zehomoni nazo zanda.
Ngokomzekelo, inokunyangwa ukuphuculwa kweesekethe zokuqhuba imithambo-luvo (i-neuralgia, njl. njl.), ukuphuculwa kokugonyeka, ukuphuculwa kobudlolo kumadoda nabasetyhini, ukomelezwa kwemisipha kunye namathambo, ukuphuculwa kokulungelelana kwehomoni (ukuphuculwa koxinzelelo lwegazi). isikhumba), ukwanda kwe-melatonin (ukuphuculwa kokulala), kunye nokuguga kwengqondo okubangelwa yi-Alzheimer's, isifo sika-Parkinson, i-ischemic encephalopathy kunye nezinye izifo.
Okwangoku kukho uphando oluninzi lokuphonononga iziphumo zokulwa nokuguga kwe-NMN kwiiseli ezahlukeneyo kunye nezicubu. Kodwa uninzi lomsebenzi lwenziwa kwi-vitro okanye kwiimodeli zezilwanyana. Nangona kunjalo, zimbalwa iingxelo zoluntu malunga nokhuseleko lwexesha elide kunye nokusebenza kweklinikhi yokuchasana nokuguga kwe-NMN ebantwini. Njengoko kunokubonwa kuphononongo olungentla, kuphela inani elincinci kakhulu lezifundo zangaphambi kweklinikhi kunye nezonyango eziphande ukhuseleko lolawulo lwexesha elide lwe-NMN.
Nangona kunjalo, sele kukho izongezo ezininzi ze-NMN zokulwa nokuguga kwimarike, kwaye abavelisi bazithengisa ngokusebenzayo ezi mveliso besebenzisa i-in vitro kunye neziphumo ze-vivo kuncwadi. Ngoko ke, umsebenzi wokuqala kufuneka ube kukuseka i-toxicology, i-pharmacology, kunye neprofayili yokhuseleko lwe-NMN ebantwini, kubandakanywa nezigulana ezinempilo kunye nezifo.
Kukho konke, ezininzi iimpawu kunye nezifo zokuncipha kokusebenza okubangelwa "ukuguga" kuneziphumo ezithembisayo.
Ixesha lokuposa: May-21-2024
